TY - JOUR
T1 - Inhibition of nitric oxide synthase with pyrazole-1-carboxamidine and related compounds
AU - Southan, Garry J.
AU - Gauld, Douglas
AU - Lubeskie, Andrew
AU - Zingarelli, Basilia
AU - Cuzzocrea, Salvatore
AU - Salzman, Andrew L.
AU - Szabó, Csaba
AU - Wolff, Donald J.
N1 - Funding Information:
This work was supportedi,n part, by NIH
PY - 1997/8/1
Y1 - 1997/8/1
N2 - Guanidines, amidines, S-alkylisothioureas, and other compounds containing the amidine function (-C(=NH)NH2) have been described as inhibitors of the generation of nitric oxide (NO) by NO synthase (NOS). Mere we report on the inhibition of the activity of NOS isoforms by compounds in which the amidine function is attached to a nitrogen of 1,2 diazo heterocycles to form N-carboxamidines and related compounds. 1H-Pyrazole-1-carboxamidine HCl (PCA) inhibited the activity of purified inducible NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS) isoforms to a similar extent (IC50 = 0.2 μM). 3-Methyl-PCA and 4-methyl-PCA showed reduced potencies, but a preference for iNOS [IC50 = 5 and 2.4 μM, respectively; cf. N(G)-methyl-L-arginine (NMA) IC50 = 6 μM]. Inhibition of purified iNOS by PCAs could be reversed completely by excess L arginine, while their inhibition of NO production by stimulated RAW macrophages could be reversed by transfer to a drug-free medium. This suggests a competitive mode of inhibition. PCA caused potent concentration dependent inhibition of the acetylcholine-induced, endothelium-dependene relaxations of precontracted rat thoracic aorta (IC50 = 30 μM). 4-Methyl-PCA inhibited the relaxations only at ≤300 μM. In contrast, 4-methyl-PCA was more effective than both PCA and NMA in restoring the ex vivo contractility of aortic rings taken from lipopolysaccharide-treated rats. PCA and NMA, but not 4-methyl-PCA, caused marked increases in mean arterial pressure when administered i.v. to anesthetized rats. In conclusion, PCA and related compounds caused potent inhibition of NOS. Substitution of the pyrazole ring reduced potency, but improved selectivity towards iNOS as exemplified by 4-methyl-PCA.
AB - Guanidines, amidines, S-alkylisothioureas, and other compounds containing the amidine function (-C(=NH)NH2) have been described as inhibitors of the generation of nitric oxide (NO) by NO synthase (NOS). Mere we report on the inhibition of the activity of NOS isoforms by compounds in which the amidine function is attached to a nitrogen of 1,2 diazo heterocycles to form N-carboxamidines and related compounds. 1H-Pyrazole-1-carboxamidine HCl (PCA) inhibited the activity of purified inducible NOS (iNOS), endothelial NOS (eNOS), and neuronal NOS (nNOS) isoforms to a similar extent (IC50 = 0.2 μM). 3-Methyl-PCA and 4-methyl-PCA showed reduced potencies, but a preference for iNOS [IC50 = 5 and 2.4 μM, respectively; cf. N(G)-methyl-L-arginine (NMA) IC50 = 6 μM]. Inhibition of purified iNOS by PCAs could be reversed completely by excess L arginine, while their inhibition of NO production by stimulated RAW macrophages could be reversed by transfer to a drug-free medium. This suggests a competitive mode of inhibition. PCA caused potent concentration dependent inhibition of the acetylcholine-induced, endothelium-dependene relaxations of precontracted rat thoracic aorta (IC50 = 30 μM). 4-Methyl-PCA inhibited the relaxations only at ≤300 μM. In contrast, 4-methyl-PCA was more effective than both PCA and NMA in restoring the ex vivo contractility of aortic rings taken from lipopolysaccharide-treated rats. PCA and NMA, but not 4-methyl-PCA, caused marked increases in mean arterial pressure when administered i.v. to anesthetized rats. In conclusion, PCA and related compounds caused potent inhibition of NOS. Substitution of the pyrazole ring reduced potency, but improved selectivity towards iNOS as exemplified by 4-methyl-PCA.
KW - Blood pressure
KW - Inhibition
KW - L-arginine
KW - Nitric oxide sythase
KW - Pyrazole-1-carboxamidine
UR - http://www.scopus.com/inward/record.url?scp=0030824733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030824733&partnerID=8YFLogxK
U2 - 10.1016/S0006-2952(97)00196-2
DO - 10.1016/S0006-2952(97)00196-2
M3 - Article
C2 - 9278100
AN - SCOPUS:0030824733
SN - 0006-2952
VL - 54
SP - 409
EP - 417
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 3
ER -